Ananda Developments Plc

🍃 Learn about the therapeutic potential of cannabidiol (CBD) at our FREE webinar next week! Join us Tuesday 17 September from 2pm BST as six speakers discuss the latest data on the anti-inflammatory mechanisms of CBD, results from pre-clinical and clinical studies and the pharmacokinetic and formulation challenges faced in its development as a therapeutic. 🆓 Book your FREE ticket now: https://lnkd.in/eqEY9SeJ Speakers and talks: ⚕ 'Ananda Developments' Dr Katie Sloper, Medical Researcher at Ananda Developments Plc, UK ⚙ 'Mechanisms of anti-inflammatory effects of cannabidiol' Professor Oliver Werz, Professor for Pharmaceutical Chemistry at Friedrich Schiller University Jena, Germany 🫀 'Is the cardiovascular system a therapeutic target for cannabidiol? – antifibrotic/antiproliferative potential of cannabidiol' Dr Marta Baranowska-Kuczko, Department of Experimental Physiology and Pathophysiology; Head of the Department of Clinical Pharmacy at Medical University of Bialystok, Poland Anna Krzyżewska, PhD student at the Department of Experimental Physiology and Pathophysiology at Medical Sciences at the Medical University of Białystok, Poland 🤲 'CBD for the management of chronic chemotherapy-induced peripheral neuropathy - early insights from the ACTION Trial' Professor Marie Fallon, Professor of Palliative Medicine at the Usher Institute, The University of Edinburgh, UK 🚧 Challenges of oral cannabidiol delivery Dr Andrejs Sitvos, Researcher and Lecturer at the Rīga Stradiņš University, Latvia Chairs: Professor Cherry Wainwright, Robert Gordon University Professor clive page, King's College London, UK #Cannabidiol #CBD # CBDTherapy #CBDTreatment #Inflammation #AntiInflammatory #Antifibrotic #Antiproliferative #PeripheralNeuropathy #Chemotherapy

Watch our Finance Director Jeremy Sturgess-Smith speak to Proactive from LSX USA Congress in Boston. Jeremy shares insights on our recent £2.15 million fundraising, which will primarily support the manufacture of MRX1 for two Phase 2 studies. Additionally, he discusses the company's plans to focus on moving MRX1 through pretrial regulatory pathways over the next six months, with plans to conduct a pharmacokinetic study in Australia due to its world-class Phase 1 study ecosystem. Watch the full video here: https://lnkd.in/ebYGGRZs

Good luck and have a great time, Jeremy

We welcome questions via our InvestorHub page: 09/09/24 Q: “I put my pension pot into GWP, but shorted out just before they launched on NASDAQ, so what are you doing that they haven't already done to give you real commercial traction?” A: "What we have done is to focus on areas of high unmet need, as specifically laid out by NICE. This gives us enhanced access to grant funding and accelerated regulatory pathways. We believe this puts us in an advantageous position for market authorisation, licencing and NICE recommendation." Answered by Jeremy Sturgess-Smith, Finance Director https://lnkd.in/esRrvTcc - Melissa Sturgess Jeremy Sturgess-Smith

£2.15m gives us a good runway to hit some key value accretive milestones.

Placing and Subscription to raise c.£2.15 million Launch of WRAP Retail Offer Ananda Developments is also pleased to announce that it has successfully raised gross proceeds of £2,145,861 from new and existing shareholders by way of a placing and subscription of new Ordinary Shares at a price of 0.3 pence per share. https://lnkd.in/ewde_reN Melissa Sturgess Jeremy Sturgess-Smith

We welcome questions via our InvestorHub page: 09/09/24 Q. Do you know whether HL will be participating in the WRAP Retail Offer? A. They should be able to participate yes. We'd recommend calling them directly and relaying the contents of our RNS to them for confirmation. Answered by: Jeremy Sturgess-Smith, Finance Director - https://lnkd.in/eFY97cXZ Melissa Sturgess Jeremy Sturgess-Smith

Ananda Developments - WRAP Retail Offer for up to £100,000 Ananda Developments is pleased to announce a retail offer via the Winterflood Retail Access Platform ("WRAP") to raise up to £100,000 through the issue of new ordinary shares of 0.2p each in the capital of the Company. Read more: https://lnkd.in/eFY97cXZ Melissa Sturgess Jeremy Sturgess-Smith

Ananda Developments is pleased to present our latest whitepaper, "An introduction to Cannaboidiol (CBD) as a Pharmaceutical Medicine." Authored by Ananda Advisor Dr. Katie Sloper and Ananda Chairman Charles Morgan, this document provides an in-depth analysis of the therapeutic potential of CBD. This whitepaper highlights: - The extensive therapeutic potential for CBD across various medical conditions. - Detailed insights into the clinical trials being conducted by our subsidiary, MRX Medical,  in endometriosis and chemotherapy-induced peripheral neuropathy (CIPN): two complex inflammatory pain conditions with high unmet clinical need  . - The future trajectory of CBD as a regulated pharmaceutical product Ananda Developments remains committed to the development of CBD-based therapies for complex chronic diseases. We hope this whitepaper is a useful resource for shareholders, investigators interested in clinical trials using CBD and other stakeholders and professionals in the pharmaceutical and healthcare sectors. Download the report here: https://shorturl.at/UJ9vb Melissa Sturgess Jeremy Sturgess-Smith